144
Participants
Start Date
January 31, 2013
Primary Completion Date
July 31, 2013
Study Completion Date
July 31, 2013
Oral testosterone undecanoate
Initial dose 200 mg T, BID; dose titration Days 42 and/or 84 based on serum T levels obtained 3-5 hours post AM dose on Days 30 and 72. Dosages increased or decreased in 50 mg increments.
University Urology Associates, New York
Unrologic Consultants of SE Pennsylvania, Bala-Cynwyd
Jacksonville Impotence Treatment Center, Jacksonville
South Florida Medical Research, Aventura
PAB Clinical Research, Brandon
Innovative Research of West Florida, Clearwater
Alabama Clinical Therapeutics, LLC, Birmingham
Alabama Internal Medicine, PC, Birmingham
Medical Affliated Research Center, Inc., Huntsville
Research Across America, Carrollton
Research Across America, Dallas
Potenium Clinical Research, LLC, Hurst
Clinical Trial Network, Houston
Clinical Trials of Texas, Inc., San Antonio
Premier Clinical Research Center, Phoenix
Precision Trials/Valley Urologic Associates, Phoenix
Precision Trials/Valley Urologic Associates, Glendale
Quality of LIfe Medical and Research Center, Tucson
Tower Urology, Tower Research Institute, Los Angeles
LABiomedical Research Institute at Harbor-UCLA Medical Center, Torrance
San Diego Sexual Medicine, San Diego
South ORange County Endocrinology, Laguna Hill
SC Clinical Research, Inc., Garden Grove
Sunstone Medical Research, Medford
Rainer Clinical Research Center, Inc., Renton
University of Washington, Seattle
Conneticut Clinical Research Center, Middlebury
Lead Sponsor
Collaborators (1)
inVentiv Health Clinical
OTHER
Clarus Therapeutics, Inc.
INDUSTRY